Quick Takeaways: Why It Matters? VetrixBio is testing a dual-action osteoarthritis therapy that targets both pain (NGF/TrkA) and cartilage degradation (ADAMTS-5) in dogs, rather than just providing analgesia. The clinical data in aged Beagles shows a single...
Quick Takeaways: Why It Matters? Lenivia strengthens Zoetis’ lead in monoclonal antibody–based pain management for dogs by adding a longer-acting OA option to its portfolio. Market-wise, a single injection providing up to three months of osteoarthritis pain...
Quick Takeaways: Why It Matters? ALA-1000’s data support a true once-monthly, long-acting analgesic option, which could meaningfully shift osteoarthritis pain management away from daily oral medications in suitable dogs. If approved, the combination of dura...
